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Background: Levosimendan is a calcium sensitizer that has been shown to prevent
myocardial contractile depression in patients post cardiac surgery. This drug exhibits an
anti-apoptotic property; however, the underlyingmechanism remains elusive. In this report,
we characterized the myocardial protective of levosimendan in preventing cardiomyocyte
apoptosis and post-operative stunning in an experimental ischemia–reperfusion model.
Methods: Three groups of pigs (n= 8 per group) were subjected to 40min of global,
cardioplegic ischemia followed by 240min of reperfusion. Levosimendan (65μg/kg body
weight) was given to pigs by intravenous infusion (L-IV) before ischemia or intracoronary
administration during ischemia (L-IC). The Control group did not receive any levosimendan.
Echocardiography was used to monitor cardiac function in all groups. Apoptosis levels
were assessed from the left ventricle using the terminal transferase mediated dUTP nick
end labeling (TUNEL) assay and immunocytochemical detection of Caspase-3. Results:
Pigs after ischemia–reperfusion had a much higher TUNEL%, suggesting that our treat-
ment protocol was effective. Levels of apoptosis were signiﬁcantly increased in Control
pigs that did not receive any levosimendan (0.062± 0.044%) relative to those received lev-
osimendan either before (0.02± 0.017%, p = 0.03) or during (0.02± 0.017%, p = 0.03) the
ischemia phase. Longitudinal left ventricular contraction in pigs that received levosimendan
before ischemia (0.75± 0.12mm) was signiﬁcantly higher than those received levosimen-
dan during ischemia (0.53± 0.11mm, p = 0.003) or Control pigs (0.54± 0.11mm, p = 0.01).
Conclusion:Our results suggested that pigs received levosimendan displayed a markedly
improved cell survival post I–R.The effect on cardiac contractility was only signiﬁcant in our
perfusion heart model when levosimendan was delivered intravenously before ischemia.
Keywords: myocardial protection, apoptosis, ischemia/reperfusion injury, animal model
INTRODUCTION
A successful myocardial protection during open heart surgery has
an important clinical signiﬁcance for overall short- and long-
term outcome. Ischemia–reperfusion injury and concomitantly
induced cardiomyocyte apoptosis (Gottlieb et al., 1994; Wu et al.,
2003) continue to be unresolved issues in cardiac surgery and
therefore better means for myocardial protection are needed.
Levosimendan is a novel calcium sensitizer, which is used to
improve myocardial contractility by stabilizing troponin C, and
enhancing calcium sensitivity of cardiac myoﬁlaments in heart
failure patients (Hasenfuss et al., 1998; Kivikko et al., 2002). Lev-
osimendan has been successfully used in open heart surgery to
treat post-operative heart failure and a recent randomized clinical
trial showed, that peri-operative levosimendan infusion facilitates
weaning from cardiopulmonary bypass at coronary bypass surgery
in patients with impaired left ventricular (LV) function (Eriksson
et al., 2009). Systemic hypotension may limit the intravenous use
of levosimendan and therefore, intracoronary administration has
been proposed as an alternative strategy to provide optimal dis-
tribution in the heart (Grossini et al., 2005, 2010; Caimmi et al.,
2006).
Several in vitro and in vivo studies including models of acute
coronary ischemia and cardiac dysfunction show, that levosimen-
dan provides myocardial protection by inducing preconditioning
of the myocardium against peri-operative ischemia–reperfusion
injury and by involving apoptotic pathway (Maytin and Colucci,
2005; Louhelainen et al., 2007; du Toit et al., 2008; Meyer et al.,
2008; Grossini et al., 2010). The direct effect of levosimendan on
cardiomyocyte apoptosis is believed to act through ATP-sensitive
potassium channels in cardiac mitochondria (Kopustinskiene
et al., 2004;Maytin and Colucci, 2005). The anti-apoptotic mecha-
nism of levosimendan is postulated to explain its cardioprotective
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effect at least in part (Louhelainen et al., 2007), although, it is
not known whether levosimendan has protective effects against
cardiomyocyte apoptosis during open heart surgery. The effect
of intracoronary delivery of levosimendan during ischemia on
myocardial protection has not been studied.
In order to further elucidate the therapeutic effects of levosi-
mendan in ischemia–reperfusion injury, we used a pig model of
open heart surgery to ﬁnd out whether levosimendan is able to
reduce cardiomyocyte apoptosis and preserve left ventricle func-
tion after cardiopulmonary bypass and cardioplegic cardiac arrest.
We also aimed to determine whether timing and mode of adminis-
tration of levosimendan has impact on the cardioprotection, using
intravenous infusion before ischemia and intracoronary infusion
at the inception and during ischemia.
MATERIALS AND METHODS
EXPERIMENTAL MODEL
This study was performed using an experimental open heart
surgery model of ischemia–reperfusion injury with pigs (n = 24,
mean weight 30± 0.7 kg). In brief, after induction of anesthesia
with ketamine and diazepam, all animals were intubated by tra-
cheostomy and ventilated with 60% oxygen. Both external jugular
veins and right common carotid artery were cannulated. Anes-
thesia was maintained with continues infusion of ketamine and
pancuronium. The heart was exposed by median sternotomy and
the animals were connected to cardiopulmonary bypass by using
a two-stage cannula in right atrium and an aortic cannula in the
ascending aorta. Animals were kept in normothermia during the
experiment.After the aortawas cross-clamped,all animals received
500 ml cold, crystalloid cardioplegia (modiﬁed St. Thomas II,
+5˚C) administered antegrade to the ascending aorta to achieve
cardiac arrest. After 20 min of ischemia, an additional 500 ml
dose of cardioplegia was given. Aortic cross-clamp was removed
after 40 min of ischemia, deﬁbrillation was performed in case of
ventricular ﬁbrillation and the animals were weaned from the car-
diopulmonary bypass as soon as possible. Animals were sacriﬁced
after 240 min of reperfusion at the end of experiment with an
injection of potassium chloride. All animals received humane care
in compliance with the European Convention on Animal Care.
The study protocol was reviewed and approved by the Ethical
Committee for Animal Experiments of the University of Turku.
INTERVENTIONS
In this study, the animals were openly randomized in to
three groups, Figure 1: (1) L-IV group received levosimendan
(65μg/kg: 10 min intravenous infusion 35μg/kg+ 30 min infu-
sion 1μg/kg/min) 40 min before cold, cardioplegic ischemia, (2)
L-IC group received an equal dose of levosimendan (65μg/kg)
mixed with the cardioplegia solution, (3) Control group did not
receive levosimendanduring the experiment. In theL-IVgroup the
levosimendan was mixed with 98 ml of 5% glucose solution. The
L-IC group received levosimendan during cardioplegia adminis-
tration, mixed with 1000 ml of cardioplegia solution, given in two
doses: after cross-clamping the aorta (500 ml) and after 20 min of
ischemia (500 ml). Both in the L-IC and in the Control groups
the animals received 10 min intravenous bolus followed by 30 min
infusion of 5% glucose solution (45 ml) before cross-clamping the
aorta. The levosimendan doses were determined according to an
earlier pilot study (n = 7).
ASSESSMENT OF MYOCARDIAL AND BLOOD LEVOSIMENDAN
CONCENTRATION
The concentrations of levosimendan and its metabolites OR-1855
and OR-1896 (Kivikko et al., 2002) were assessed from the frozen
myocardial samples at the end of the experiment, and from the
frozen plasma samples taken 110, 170, 260, and 320 min after
starting the levosimendan by a validated liquid chromatography –
tandemmass spectrometricmethod. Levosimendan,OR-1855 and
OR-1896 were extracted from plasma or heart homogenate with
a mixture of ethyl acetate and hexane. The organic layer was sep-
arated and the solvent was evaporated into dryness. The residue
was dissolved into the mobile phase. The analytes were isolated
with isocratic elution in an Atlantis™dC18, 2.1 mm× 100 mm
(5μm) column followed by an electrospray ionization with a
TurboIonSpray interface and detected using the selected reaction
monitoring.
FIGURE 1 |The timing of the levosimendan doses during the
experiment. L-IV group= levosimendan (65μg/kg) given
intravenously before ischemia, L-IC group= levosimendan (65μg/kg)
given intracoronary during ischemia in two doses (I and II). During
ischemia, all animal were connected to the cardiopulmonary bypass and
ischemia was induced using aortic cross-clamp and cold, crystalloid
cardioplegia. The reperfusion period was 240min. i.v., Intravenous, i.c.,
intracoronary.
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DETECTION OF CARDIOMYOCYTE APOPTOSIS
Transmyocardial samples were obtained from the left ventricle
in order to detect cardiomyocyte apoptosis. Samples were taken
before ischemia with a needle (Tru-Cut®,Cardinal Health,McGaw
Park, IL 60085,USA) and after ischemia–reperfusion period at the
end of the experiment by removing the heart. Samples were ﬁxed
in neutral buffered formalin over night, embedded in parafﬁn,
and cut at 4μm sections for analysis of apoptosis. Cardiomyocyte
apoptosis was detected using terminal transferase mediated dUTP
nick end labeling (TUNEL) assay and immunohistochemistry of
cleaved caspase-3 as previously described (Vahasilta et al., 2005;
Malmberg et al., 2006).
ECHOCARDIOGRAPHY AND HEMODYNAMIC MONITORING
Echocardiography was performed epicardially to all animals at
the beginning of the experiment after median sternotomy before
manipulating the heart and was repeated at the end of the experi-
ment. The animals were studied in supine position. Measurements
were performed using Acuson Sequoia C512 (Acuson Inc., Moun-
tain View, CA, USA) instrument with 4V1c 4 MHz and 15L8
transducers and recorded in digital mode. Results are the aver-
ages of three measurements. Longitudinal contraction of the left
ventricle was measured as displacement of the lateral annulus in
M-mode using a transducer position equivalent to transthoracic
apical four-chamber view.Also left ventricle ejection fraction, early
(E) and atrial (A) mitral inﬂow velocities were recorded. Coronary
ﬂow was calculated by multiplying heart rate with velocity time
integral from the mid left anterior descending artery. Our group
has earlier validated transthoracic echocardiography for measur-
ing coronary ﬂow (Kiviniemi et al., 2007) and in this study the
method was further applied using epicardial data acquisition to
allow us to detect even small changes in coronary ﬂow. Moreover,
our recent paper showed that coronary echocardiography can be
used to predict viability after acute infarction (Saraste et al., 2007).
Cardiac out-put, pulmonary capillary wedge pressure and
central venous pressure were monitored through the experi-
ment by placing a pediatric thermodilution catheter (Swan-
Ganz®, Edwards Lifesciences LLC, Irvine, CA, USA) into the
pulmonary artery from the right external jugular vein. Also
electrocardiography, heart rate and mean arterial pressure were
monitored.
STATISTICAL ANALYSIS
Power analysis indicated eight animals per group based on the
observed variability in apoptosis (0.014% after injury) and lon-
gitudinal contraction (0.10 mm) in our preliminary work. Cal-
culation was based on following details and assumptions (power
of 0.8, two-sided test, alpha 0.05, differences of 50% in apopto-
sis and 20% in longitudinal contraction between the groups). In
order to determine whether the data was normally distributed, the
Shapiro–Wilk test was applied. Normally distributed, continuous
variables are expressed as mean± SD. Non-parametric variables
are expresses as median and interquartile range (IQR). The differ-
ences between the groups were tested with one-way ANOVA with
Tukey HSD post hoc-tests or Kruskal–Wallis-test, and the latter
tests were continued with Mann–Whitney U test when needed.
The differences within a group were tested with Two-tailed paired
T -test or Mann–Whitney U test. Differences were considered sig-
niﬁcant if the p-value was <0.05. All analyses were performed
using SPSS software package (Version 16.0; SPSS, Inc., Chicago,
IL, USA).
RESULTS
All animals survived the study protocol. The intravenous infu-
sion as well as intracoronary administration of levosimendan was
well tolerated. There were no signiﬁcant hypotension or other
hemodynamic problems.
CARDIOMYOCYTE APOPTOSIS
In the beginning of the experiment, before (pre) the ischemia–
reperfusion, there were only few apoptotic cardiomyocytes and
no signiﬁcant differences between the groups. Intense positive
TUNEL staining in the nucleus and positive immunostaining
for active caspase-3 in the nucleus and in the cytoplasm were
seen in the tissue samples taken after (post) the ischemia–
reperfusion period, Figure 2. Apoptosis induction was conﬁrmed
by TUNEL assay in all three (pre L-IV 0.002± 0.004% vs. post
L-IV 0.020± 0.017% p = 0.02, pre L-IC 0.001± 0.004% vs. post
L-IC 0.02± 0.017% p< 0.001,pre control 0.007± 0.013%vs. post
control 0.062± 0.044% p = 0.01), Figure 3. At the end of the
experiment, there were three times more apoptotic cardiomy-
ocytes in the control group when compared with the L-IV group
(p = 0.03) and L-IC group (p = 0.03), but the amounts of apop-
tosis were comparable in the groups that received levosimendan
(p = 1.00).
ECHOCARDIOGRAPHY
Detailed echocardiography data is presented in Table 1. Systolic
LV function as assessed by the longitudinal motion of the lateral
mitral valve annulus,was comparable in all groups before ischemia
(adjusted p = 0.77). However, longitudinal systolic motion of the
lateral mitral annulus was signiﬁcantly reduced in the L-IC and the
control groups when compared to the L-IV group (L-IV vs. L-IC
p = 0.003, L-IV vs. control p = 0.01). The difference between the
L-IC and control groups was not signiﬁcant (p = 0.97). Consistent
FIGURE 2 | ATUNEL-positive cardiomyocyte (nucleus) after
ischemia–reperfusion in the left ventricle.
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FIGURE 3 | Cardiomyocyte apoptosis as detected by theTUNEL assay
in the left ventricular myocardial biopsies obtained before (pre) and
after (post) the ischemia–reperfusion. L-IV, levosimendan infusion-group;
L-IC, intracoronary levosimendan-group. **Post L-IV vs. post control
p =0.03, post L-IC vs. post control p =0.03.
with these ﬁndings, ejection fraction was signiﬁcantly reduced at
the end of the experiment in the L-IC (p = 0.04) and the con-
trol (p = 0.02) groups, but not in the L-IV (p = 0.07) group as
compared with pre-ischemic values. However, no signiﬁcant dif-
ferences were detected in ejection fraction between the groups at
the end of the experiment.
The coronary ﬂow was comparable in L-IV, L-IC, and con-
trol groups at the beginning of the experiment. However, after
the ischemia–reperfusion injury, there was a tendency toward
higher coronary ﬂow in both levosimendan treatment groups
compared to the control group (L-IV 9.33± 3.55 m/s vs. con-
trol 7.03± 2.43 m/s p = 0.40, L-IC 8.77± 3.83 m/s vs. control
p = 0.58).
Early diastolic left ventricle ﬁlling velocity, i.e., mitral inﬂow
E-wave velocity, was signiﬁcantly reduced after the ischemia–
reperfusion injury in all three groups. At the beginning of
the experiment, there were no differences between the groups
(adjusted p = 0.56). At the end of the experiment, there were
no signiﬁcant differences between control and L-IV (p = 0.85)
or between control and L-IC (p = 0.06) groups, but we found a
signiﬁcant difference between L-IV and L-IC groups (p = 0.01).
In the other echocardiography variables no signiﬁcant differences
between were detected in phase of the study.
HEMODYNAMIC MEASUREMENTS
Detailed hemodynamic data is presented in Table 2. Com-
pared with preoperative values, cardiac out-put was signiﬁcantly
decreased in all groups at the end of the experiment. At this time,
cardiac out-put was signiﬁcantly lower in L-IC group compared
to control group (p = 0.04), but it was comparable between L-IV
and L-IC groups (p = 0.08) as well as L-IV and control groups
(p = 0.87). There was already at the beginning of the experi-
ment a signiﬁcant difference between the L-IV and control groups
(p = 0.04), but not between the L-IV and L-IC (p = 0.09) or
between theL-IC and control groups (p = 0.81). Thus, the absolute
Table 1 | Echocardiography data at the beginning (pre) and at the end
of the experiment (post).
L-IV L-IC Control
E (m/s)
Pre 0.67±0.09 0.63±0.12 0.71±0.1
Post 0.46±0.07* 0.35±0.06* 0.44±0.04*
A (m/s)
Pre 0.67±0.14 0.57±0.12 0.71±0.19
Post 0.61±0.15 0.48±0.11 0.49±0.1*
E/A
Pre 1.05±0.29 1.11[0.11] 1.03±0.08
Post 0.72[0.28] 0.78±0.22* 0.93±0.17
E′/A′
Pre 0.97±0.37 0.79±0.97 1.08±0.3
Post 0.76±0.17 0.81±0.35 0.92±0.29
EF (%)
Pre 71.07±2.89 69.12±6.37 68.13±6.64
Post 62.62±10.9 59.42±4.52* 60.07±4.47*
Longit lat (mm)
Pre 0.76±0.20 0.78±0.13 0.82±0.14
Post 0.75±0.12 0.53±0.11* 0.54±0.11*
Coronary ﬂow (m/s)
Pre 9.06±5.32 7.32±1.52 5.1[1.69]
Post 9.33±3.55 8.78±3.84 7.03±2.43
MDV (m/s)
Pre 0.25[0.09] 0.25±0.05 0.21±0.06
Post 0.28±0.08 0.26±0.11 0.23±0.06
Data presented as mean±SE of mean or median and (interquartile range). L-IV,
levosimendan infusion-group; L-IC, intracoronary levosimendan–group. E, early;
A, late mitral inﬂow velocity; E′/A′, velocity ratio on the mitral annulus; EF, ejec-
tion fraction; Longit lat, longitudinal systolic motion of the lateral mitral annulus;
MDV, mean diastolic coronary ﬂow. *p<0.05 pre vs. post.
decrease between pre-and post-ischemic cardiac out-put was sig-
niﬁcantly lower in L-IV than control group (p = 0.03), whereas
it was comparable between L-IV and L-IC (p = 0.93) as well as
L-IC and control groups (p = 0.06). Mean arterial pressure was
signiﬁcantly higher at the end of the experiment only in the L-IV
group when compared to the values measured at the beginning of
the experiment (pre vs. post p = 0.01). Calculated systemic vas-
cular resistance [SVR= (mean arterial pressure− central venous
pressure)/cardiac out-put] was signiﬁcantly increased in all three
groups during the experiment, but there were no signiﬁcant differ-
ences between the groups. The absolute increase in SVR (post–pre)
was signiﬁcantly higher in L-IC than control group (p = 0.04),
whereas it was comparable between L-IV and control (p = 0.18)
as well as L-IV and L-IC groups (p = 0.74). There were no other
signiﬁcant differences between the groups or between pre- and
post-experimental values.
CONCENTRATIONS OF LEVOSIMENDAN, OR-1855 AND OR-1896
We detected effective doses of either levosimendan or its active
metabolite OR-1896 in the myocardium or plasma samples after
both intracoronary and intravenous administration. The levosi-
mendan concentration was signiﬁcantly higher in the L-IC group
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Table 2 | Results of the hemodynamic measurements at the beginning
(pre) and at the end of the experiment (post).
L-IV L-IC Control
CO (l/min)
Pre 4.07±0.70 3.38±0.37 3.23±0.37
Post 2.28±0.61* 1.57±0.23* 2.00±0.35*
MAP (mmHg)
Pre 61.88±8.71 65.88±14.5 61.00±8.11
Post 83.5±17.71* 85.38±21.82 80.25±17.90
HR (/min)
Pre 105.13±16.39 111±9.99 106.13±20.1
Post 105.5±23.13 108.63±12.97 105.86±12.9
CVP (mmHg)
Pre 3.63±3.70 3.13±0.99 2.88±0.83
Post 3.13±3.04 4.25±2.05 4.38±1.30
PCWP (mmHg)
Pre 3.75±3.77 4.25±1.67 4.38±2.2
Post 3.13±3.18 5.5±4.44 3.75±1.16
SVR
Pre 14.51±1.48 18.67±4.11 18.28±3.88
Post 38.63±9.90* 51.42±9.38* 38.95±11.2*
Calculated SW
Pre 2.49±0.92 2.02±0.59 1.93±0.52
Post 1.86±0.93 1.25±0.43 1.54±0.49
Data presented as mean±SEM. L-IV, levosimendan infusion-group, L-IC, intra-
coronary levosimendan-group. CO, cardiac out-put; MAP, mean arterial pressure;
HR, heart rate; CVP, central venous pressure; PCWP, pulmonary capillary wedge
pressure; SVR, systemic vascular resistance, Calculated SW= left ventricle stroke
work= (CO/HR)×MAP. *p<0.05 pre vs. post, p<0.05 between groups (values
in bold).
than in the L-IV group in the myocardial biopsies taken at the end
of the experiment, Figure 4. In the myocardial samples no traces
of metabolites OR-1855 or OR-1896 were found. In the plasma
samples taken during the experiment, metabolite OR-1896, but
no traces of levosimendan or metabolite OR-1855 was detected,
Figure 5. The concentrations of OR-1896 were signiﬁcantly higher
in the L-IC group than in the L-IV group 170 min (p = 0.001) and
260 min (p = 0.004) after levosimendan. At 110 min (p = 0.08)
and 320 min (p = 0.28) there were no signiﬁcant differences.
DISCUSSION
The main result of this study with an in vivo pig model of open
heart surgery is that levosimendan administered intracoronary
during ischemia provides cardioprotective effect, demonstrated
by reduced myocardial apoptosis at acute phase of ischemia–
reperfusion injury after cardiopulmonary bypass and cardioplegic
cardiac arrest. Although both administration modes of levosimen-
dan prevented similarly apoptosis, preoperatively started intra-
venous administration was superior to intracoronary started at
the time of ischemia–reperfusion, assessed by echocardiography-
derived systolic cardiac function. This suggests that intravenous
preoperative administration may be more effective in preventing
the post-operativemyocardial stunning, as compared to intracoro-
nary administration at the beginning and during ischemia.
FIGURE 4 | Levosimendan concentrations at the end of the experiment
in the left ventricular myocardial samples. L-IV, levosimendan
infusion–group; L-IC, intracoronary levosimendan-group. *p =0.001.
FIGURE 5 | Concentration of metabolite OR-1896, the active
metabolite of levosimendan in the plasma samples 110, 170, 260, and
320min after the onset of levosimendan administration. L-IV,
levosimendan infusion-group; L-IC, intracoronary levosimendan-group.
Levosimendan protects cardiomyocytes from apoptosis in
experimental models of cardiac pressure overload (Louhelainen
et al., 2007) and heart failure induced by viral myocarditis
(Latva-Hirvela et al., 2009). Moreover, levosimendan induces pre-
conditioning and decreases myocardial infarct size in an iso-
lated perfused rat heart model of acute ischemia–reperfusion
injury (Ozturk et al., 2010). This is the ﬁrst study to evaluate
the effects of levosimendan on cardiomyocyte apoptosis in an
in vivo experimental model of global, cardioplegic, myocardial
ischemia that closely resembles human cardiac surgery. This study
is also the ﬁrst to compare peri-ischemic intracoronary admin-
istered levosimendan to pre-ischemic intravenous levosimendan
infusion.
Thus, this study reveals a novel ﬁnding that levosimendan pre-
vents cardiomyocyte apoptosis after global ischemia–reperfusion
injury in vivo and that this anti-apoptotic effect is conferred by
both pre-ischemic intravenous administration and peri-ischemic
intracoronary administration. Intracoronary levosimendan has
www.frontiersin.org February 2012 | Volume 3 | Article 17 | 5
Malmberg et al. Intracoronary levosimendan
been successfully used after global or regional ischemia in previous
studies in order to prevent post-ischemic myocardial dysfunc-
tion and cardiomyocyte apoptosis (Jamali et al., 1997; Grossini
et al., 2005, 2010; Caimmi et al., 2006). Our results conﬁrm that
levosimendan prevents ischemia–reperfusion induced apoptosis.
Moreover, it is a novel ﬁnding that levosimendan given before cold,
global ischemia as an infusion, reduces cardiomyocyte apoptosis
equally to levosimendan given during ischemia when the doses are
comparable.
Levosimendan has been shown to prevent myocardial stun-
ning and heart failure after cardiac surgery (Eriksson et al., 2009;
Landoni et al., 2010). Our results indicate, that levosimendan
administered with cardioplegia in the beginning and during global
ischemia, is not as effective as pre-ischemic intravenous infusion
in preserving systolic and diastolic LV function after 40 min of
ischemia and 240 min of reperfusion, although levosimendan con-
centration was higher in myocardial samples and there were no
traces of metabolites. This resultmight be explainedby the fact that
pre-ischemic levosimendan has more time to effect on cardiomy-
ocytes and might have better access into the myocardium when the
infusion is normothermic, although the differences in the plasma
concentrations indicate exceptionally fast metabolism of levosi-
mendan and its metabolites OR-1855 and OR-1896 in pig. On the
other hand, fast metabolism does not explain why there was only
levosimendan and no metabolites to be found in the myocardial
samples. However, the equal amounts of apoptotic cardiomy-
ocytes after both intracoronary and intravenous levosimendan
administration support the idea of comparable direct effects on
the level of myocardium. With longer reperfusion period there
might be a greater difference in myocardial apoptosis between
the treatment groups. The beneﬁcial action of intravenous lev-
osimendan might be partly mediated by systemic effects, whereas
intracoronary administration might be limited to local cardiac
effects. Higher intracellular levosimendan concentration supports
our hypothesis of increasing the concentration of levosimendan
in themyocardiumwithout systemic hypotension. The levosimen-
dan doses used in this study were higher than in normal clinical
practise (Eriksson et al., 2009).However, theOR-1896 plasma con-
centrations found in this study closely resembles concentrations of
human studies (Lehtonen and Pöder, 2007), and it has been shown
before, that higher doses of levosimendan are needed with pig
model to see possible hemodynamic changes (Busk et al., 2006).
The favorable effects of levosimendan on systemic hemo-
dynamics include marked reduction of afterload caused by
vasodilatation (Kivikko et al., 2002). Consistent with this expla-
nation, cardiac out-put was higher in the L-IV than L-IC group
after ischemia–reperfusion. These ﬁndings also suggest that at
least after short reperfusion period, cardiomyocyte apoptosis does
not have direct effect on post-operative myocardial stunning.
In contrast to the expected hypotension, mean arterial pressure
was actually higher in animals with levosimendan treatment than
without.
In conclusion, intracoronary levosimendan during ischemia
prevents cardiomyocytes from apoptosis in experimental animal
pig model of ischemia–reperfusion injury with cardiopulmonary
bypass and cardioplegic cardiac arrest. Intracoronary administra-
tion of levosimendan at the onset and during ischemia reduces
apoptosis equally as pre-ischemic intravenous levosimendan infu-
sion, when the doses are comparable. However, pre-ischemic
intravenous infusion is associated with better preservation of LV
systolic and diastolic function when compared with peri-ischemic
intracoronary administration. With intracoronary administered
levosimendan there were higher concentrations of levosimendan
in the left ventricle muscle biopsies and active metabolite OR-1896
in the plasma samples.
LIMITATIONS
We recognize the limitations of simulating human cardiac surgery
induced ischemia–reperfusion injury using an animal model with
healthy young pigs. However, this animal model is reproducible
and well-established (Vahasilta et al., 2005; Malmberg et al., 2006).
Tominimize the loss of animals during the experiment, the follow-
up timewas limited to 240 min to allow successful completion.Our
results can not be directly applied to clinical setting and whether
the detected acute positive effects will translate to better cardiac
function and even lower mortality at long-term, remains to be
studied.
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